The aim of this study was to assess the quantitative differences in PKM2 expression between GBM (IDH wild type) and ASTROG4 (IDH R132H mutant), as well as the impact of these differences on OS, to determine whether PKM2 could serve as a prognostic marker. The gene discussed is PKM; the disease is glioblastoma.